






AHA = American Heart Association; CAD = coronary artery disease; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; HDL = high-
density lipoprotein; LDL = low-density lipoprotein.
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The literature concerning the associations between
various dietary elements and coronary artery disease
(CAD) extends from antioxidants to alcohol and from mice
to humans, through data from large observational studies
to clinical trials. The largest body of information deals with
dietary cholesterol and fat. Indeed, the only evidence-
based means identified thus far by which atherosclerotic
lesions can be retarded or even regressed is by lowering
the serum cholesterol concentration. The effects of vita-
mins, provitamins and/or other antioxidants on atheroscle-
rosis are still controversial. Elevated serum homocysteine
concentration, which has an unquestionable association
with the risk for CAD in epidemiological studies, still lacks
definitive confirmation as a causal factor in development of
atherosclerosis. We must await the results of ongoing
clinical trials, which will determine whether lowering homo-
cysteine by treatment with vitamin therapy will reduce the
incidence of CAD. Therefore, the present review is limited
to the evidence regarding dietary fats and cholesterol,
including that related to ‘functional foods’ that contain
certain newcomers to the dietary fats – phytostanol and
phytosterol esters.
Dietary fat and cholesterol
Observational studies
During the 1950s and 1960s, an indisputable relationship
between diet and CAD was identified in most of the large
epidemiological follow-up studies conducted [1]. The
abundance of dietary total fat [2–4], especially that of sat-
urated fatty acids [2,3,5,6] and cholesterol [3,4,7], was
independently related to mortality associated with CAD. In
a recent prospective cohort study in healthy women
(n = 80,082) aged 34–59 years [8], the amount of satu-
rated and trans-unsaturated fat intake was significantly
associated with increased risk for CAD during a follow-up
period of 14 years. Dietary intakes of cholesterol and total
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fat were not associated with the risk for CAD in that study.
It was estimated that replacement of 5% of energy from
saturated fat and 2% from trans-unsaturated fatty acids by
unsaturated fats would reduce the CAD risk by 42 and
53%, respectively. However, in a recent prospective
cohort study of healthy males (n = 43,757) aged
40–75 years [9], significant associations were observed
between the intakes of cholesterol, saturated fat and
trans-fatty acids, and risk of CAD during a 6-year follow
up, but these associations were attenuated following
adjustment for intake of fibre. Intake of α-linolenic acid
was inversely associated with myocardial infarction after
adjustment for age and standard risk factors.
The study populations in both of these studies [8,9] were
health professionals (nurses and male health professionals),
and it may be speculated that their dietary and living habits
may not be comparable to those of the general population.
Regarding fibre intake, the recent American Heart Associa-
tion (AHA) Dietary Guidelines [10] recommend increasing
fibre intake by increasing consumption of vegetables,
cereals, grains and fruits, but that fibre supplements are not
recommended for heart disease risk reduction.
Dietary interventions
It was shown by two large pioneering interventions
[11,12] that it is possible to reduce the incidence of CAD
by dietary means only. In those long-term controlled
studies, with up to 8- and 12-year follow-up periods, two
dietary variables were changed; the amount of dietary cho-
lesterol was reduced by approximately 40%, and fat intake
was modified to contain less saturated and more unsatu-
rated fatty acids (saturated fatty acids constituted 26% of
total fatty acids in the experimental versus 54% in the
control diet [12]; and decrease in palmitic acid and four-
fold increase in linoleic acid [11]). In accordance with
recent recommendations [10] the intake of total fat was
rather high (approximately 110 g/day in both studies).
Serum cholesterol was reduced by 13% [11] and 15%
[12]. The incidences of end-points – coronary death [12],
and nonfatal and fatal myocardial infarction and manifesta-
tions of atherosclerosis in cerebral and peripheral arteries
[11] – were significantly lower in the experimental groups
than in the control groups.
In a third intervention study, which included 1232 healthy,
40- to 49-year-old hypercholesterolaemic men [13], coro-
nary end-points were reduced by 47% over a 5-year
period through cessation of smoking and alterations in fat
intake. In that study, total fat calories were reduced to
28% in the experimental group and were 44% in the
control group. The major change was in the intake of satu-
rated fat (8% versus 18% in the intervention versus
control cohort) and cholesterol (289 mg/day versus
527 mg/day), resulting in a reduction in serum cholesterol
by 13% and in triglycerides by 20% in the intervention
group. These classical dietary intervention studies indicate
that coronary disease can be controlled by varying dietary
cholesterol and total and saturated fat intake.
In these interventions, and in most of the observational
prospective epidemiological studies, there was a clear-cut
reduction in serum cholesterol level by more than 10%.
Law et al [14] estimated that, provided serum cholesterol
is reduced by 10% (0.6 mmol/l), the decrease in risk for
CAD in 50-year-old individuals is approximately 39%, in
those aged 60 years it is approximately 27%, and in those
aged 70 years it is approximately 20%. If serum choles-
terol is reduced further, then the risk reduction is more
effective; this has recently been confirmed by five large
statin trials [15–20], including a total study population in
excess of 30,000 individuals. Reduction in serum choles-
terol level by 10% is possible by reducing dietary choles-
terol or saturated fat intake, and these dietary changes
can be expected to result in reduction in risk for CAD.
However, in many Western populations, dietary habits
have already been changed such that the diet modifica-
tions described above will usually reduce serum choles-
terol by 10%.
The physiological mechanisms by which dietary cholesterol
and saturated fatty acids increase serum cholesterol level
are well documented [21]. Abundance of dietary choles-
terol expands the small regulatory hepatic intracellular pool
of free cholesterol, which results in reduced LDL-receptor
activity, reduced LDL-cholesterol catabolism, and
increased serum total cholesterol and LDL-cholesterol
levels; this has also been demonstrated in human kinetic
studies [22,23]. The long-chain saturated fatty acids (C12-
16:0) interfere with the esterification process of free cho-
lesterol, and by this mechanism enlarge the hepatic
regulatory free cholesterol pool [21]. Similar to in dietary
cholesterol excess, LDL-receptor transcription is reduced,
resulting in diminished LDL catabolism; this has also been
observed in human kinetic studies [24,25]. Although it has
been shown that oleic acid (C18:1) increases cholesterol
esterifation in hepatocytes, diminishes the free cholesterol
pool and enhances LDL-receptor activity, epidemiological
studies [1] have not shown any consistent effect of
monounsaturated fatty acids on risk for CAD. The trans-
fatty acids increase serum total cholesterol and LDL-cho-
lesterol levels, but their importance as independent risk
factors for CAD has not consistently been verified either
[26]. However, in the recent AHA Dietary Guidelines [10],
it is recommended that intake of trans-fatty acids be
reduced because of their effect on serum cholesterol level.
n-3 Polyunsaturated fatty acids from fish oils
The numerous studies that dealt with the impact of intake
of fish-based n-3 polyunsaturated fatty acids (EPA and
docosahexaenoic acid [DHA]) on serum lipid levels have







studies was that ingestion of n-3 polyunsaturated fatty
acids from fish oils decreases serum triglycerides by
25–30%, but have little effect on total cholesterol, LDL-
cholesterol and high-density lipoprotein (HDL)-cholesterol
levels. Their effect on the incidence of CAD, however, is
more difficult to interpret. According to numerous older
and two recent large prospective observational studies
with lengthy follow-up periods, there is a clear [28] or no
[29] association between fish oil intake and risk for CAD.
In another pioneering dietary intervention study, male
patients with myocardial infarction (n = 2033) were
advised to change their dietary habits for 2 years [30].
One group was advised to reduce fat intake to 30% of
total calories, and to reduce the intake of saturated fatty
acids and increase that of polyunsaturated fatty acids
such that the polyunsaturated : saturated fatty acid ratio
was greater than 1.0. The second group was advised to
consume fatty fish two times/week or 1.5 g EPA, and a
third group was to advised to increase their intake of
cereal fibre to 18 g/day. The only statistically significant
result was a 29% reduction in 2-year all-cause mortality in
the group that consumed more fish, as compared with the
other two groups. There was a nonsignificant reduction in
CAD recurrence in both of the groups advised to alter fat
and fish consumption, as compared with the group
advised to increase fibre intake alone. Serum cholesterol
concentration fell by a very small but statistically signifi-
cant amount (3.5%) in the group that reduced dietary fat
intake, but did not change in the other two groups eating
more fish or fibre.
In a more recent intervention [31], over 11,000 coronary
patients were randomly assigned to one of four groups for
3–5 years: consumption of n-3 polyunsaturated fatty
acids, approximately 1 g/day (EPA : DHA 2:1); vitamin E
300 mg/day; both combined; and no supplementation.
There was a 10% reduction in risk for major coronary
recurrencies in the n-3 polyunsaturated fatty acids and
combined groups, with no advantage of vitamin E supple-
mentation evident. The main effect was due to reduction in
coronary (–30%) and sudden deaths (–45%), as well as
total deaths (–20%), whereas there was no difference for
nonfatal cardiovascular events between the treatment
groups. There was no significant change in total choles-
terol and HDL-cholesterol, and LDL-cholesterol increased
in the n-3 group, whereas serum triglycerides were
decreased by 3% from baseline. Accordingly, these
results demonstrate an advantageous effect of n-3 poly-
unsaturated long-chain fatty acids, especially on CAD
mortality, without changes in serum cholesterol levels. The
beneficial effects are probably due to decreased risk for
arrhythmias, improved endothelial function and vascular
dilatation, and reduced blood-clotting tendency [10]; the
mechanism and role of reduced serum triglycerides need
to be clarified further. However, the AHA Dietary Guide-
lines [10] recommend consumption of at least two serv-
ings of fish per week, especially fatty fish, in order to
benefit from cardioprotective effects.
Lyon Heart Study
This recent intervention [32], which included 605 coro-
nary patients, was conducted to evaluate whether cardiac
mortality and morbidity can be reduced by consumption of
a Mediterranean-type, α-linolenic acid-rich diet, simulating
the most beneficial diet in the Seven Countries Study [2];
in the latter study, this diet was associated with the lowest
coronary mortality rate between the various populations
studied. The Lyon Heart Study [32] was a randomized,
single-blinded, secondary prevention study, in which the
intervention group was advised to consume the following:
more bread; more root vegetables and green vegetables;
more fish; less meat such as beef, lamb and pork, which
should be replaced by poultry; more fruit; and margarine,
olive oil and rapeseed oil rather than butter and cream.
The mean follow-up time was 27 months [32], but this was
later extended to a mean of 46 months [33]. Individuals in
the intervention group consumed less cholesterol (217
versus 318 mg/day); fewer calories in fat (30.5% versus
32.7%), especially as saturated fat (8.3% versus 11.7%);
less α-linoleic acid (3.6% versus 5.3%); but more oleic
acid (13% versus 10%), three times more α-linolenic acid
(0.8% versus 0.3%) and EPA [32]; and more fibre
(19 g/day versus 15 g/day) [33] than did the control pop-
ulation. The polyunsaturated : saturated fatty acid ratio
was similar in the groups. The intake of α-tocopherol did
not differ between the groups, but ascorbic acid intake
was higher in the intervention than in the control group.
At the end of the follow-up period serum lipids and
apoprotein B levels did not differ between the groups.
However, in both groups serum total cholesterol was
reduced by approximately 5%, LDL-cholesterol by 7% and
triglycerides by 14%, and HDL-cholesterol was increased
by approximately by 10% from baseline. Whether these
changes are significant is not obvious from the results.
However, it is surprising that the serum cholesterol reduc-
tions were not larger in the intervention group, considering
the reduced amounts of dietary cholesterol and fat con-
sumed by that group.
There was a significant risk reduction of 73% in primary
end-points (cardiac mortality and morbidity) between the
experimental and control groups, even though the number
of events was low after the first follow-up period (8 versus
33). If all cardiovascular events (ie cardiac death, nonfatal
infarction, unstable angina, heart failure, stroke and throm-
boembolism) were combined, then the survival curves dif-
fered between the groups within the first year [34]. After
the prolonged follow up, the protective effect of the diet
was maintained, and fewer primary end-point events
occurred in the experimental group than in the control
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group (14 versus 44) [33]. Also, the number of secondary
end-points (ie unstable angina, stroke, heart failure, pul-
monary or peripheral embolism) was significantly dimin-
ished, such that the reduced risk ratios varied from 0.28
for primary end-points to 0.53 for combined total primary,
secondary and minor secondary end-points. Furthermore,
after the extended follow up, serum lipid values were
similar between the groups. In multivariate analysis to
examine the impact of various factors on risk reduction,
the intervention diet and α-linolenic acid made significant
contributions, as did serum cholesterol level, sex, systolic
blood pressure and leucocyte count.
The results of the Lyon Heart Study suggest that, with a
change in diet, it is possible to reduce the incidence of
CAD, and that compliance with new dietary habits is feasi-
ble if instructions given to patients and surveillance are
properly conducted. Lowering of serum cholesterol level
was of similar magnitude in the experimental and control
groups, but serum cholesterol level had an independent
impact on risk reduction. The specific dietary change in
the experimental group was the different fatty-acid profile,
and higher fibre intake and ascorbic acid level. What then
was the mechanism responsible for the reduction in inci-
dence of CAD? It is well documented that reduction in
serum cholesterol level stabilizes the vulnerable plaque by
reducing the lipid core. α-Linolenic acid, the second
essential fatty acid in humans, can be elongated to the
long-chain EPA and DHA, but its other exact functions in
the human body are not characterized in detail. It is
present in abundance in retinal and brain tissues, but its
role for example in in cell membranes or signal transduc-
tion is unresolved. Accordingly, its exact mechanism of
action in reducing coronary disease recurrence is
unknown, but the AHA Dietary Guidelines [10] recom-
mend increasing its daily intake, as for the long-chain n-3
fatty acids from fish. Canola oil, soybean oil and nuts are
rich sources of α-linolenic acid. 
Plant stanol and sterol esters
Unesterified, mainly crystalline plant sterols have been
used since early 1950s in the treatment of hypercholes-
terolaemia [35]. Fat-soluble plant stanol esters were intro-
duced in 1991 for serum cholesterol lowering [36]. Plant
stanol ester margarine (Benecol; Raisio Group plc, Raisio,
Finland) has been marketed for that purpose in Finland
since 1995, when 1-year cholesterol-lowering results with
this product were reported by Miettinen [37]. At present,
the product is available in several countries in different fat
spreads, and in the form of yogurt, cheese, snack bar and
salad dressing. According to recent results [38,39], the
plant stanol ester margarine lowers serum total cholesterol
by 10–15% and LDL-cholesterol by up to 20%. In addi-
tion, the product provides a substitute for the saturated
fats in dairy spreads and for increased consumption of the
polyunsaturated fatty acids of rapeseed oil (canola oil)
margarine that is the vehicle for the stanol esters. Virtually
no harmful side effects have been observed. Plant stanol
ester margarine lowers serum cholesterol by inhibiting
sterol absorption in general, resulting not only in serum
cholesterol, but also in reduction in serum plant sterols.
Enhanced elimination of cholesterol stimulates compen-
satory cholesterol synthesis within the body [35].
During the late 1990s, based on earlier findings of
Mattson et al [40], plant sterol ester margarine was found
to lower serum cholesterol [41,42]. The reduction in
short-term studies was approximately similar to that with
the plant stanol esters, and the margarine has been mar-
keted as Becel Pro-Activ (Unilever, The Netherlands).
However, plant sterols are absorbed to a markedly higher
extent than are plant stanols. Consumption of plant sterol
esters, in contrast to that of plant stanol esters, increases
serum plant sterol concentrations. In most cases, the
increase in levels of plant sterol remains significantly
lower than that seen in phytosterolaemia, a hereditary and
strongly atherogenic clinical condition [43]. It remains
unclear whether this absorption of plant sterols offers any
risk of vascular events, because the published studies are
of short duration.
Consumption of plant stanol ester margarine lowers serum
cholesterol in normal individuals, in slightly hypercholes-
terolaemic patients, in adults and children with familial
hypercholesterolaemia, and in hypercholesterolaemic type
2 diabetic persons [35,38,39]. Cholesterol lowering does
not appear to depend on dietary cholesterol intake or fatty
acid composition. Consumption of plant stanol and sterol
esters does not appear to interfere with absorption of fat-
soluble vitamins, even though in the long term serum β-
carotene concentration may decrease. The consumption
periods of plant stanol and sterol ester studies have been
relatively short (1 year for stanol esters and several weeks
for sterol esters) and no placebo-controlled intervention
trial has been performed concerning their possible capac-
ity to reduce the incidence of coronary events. Therefore,
no evidence-based information is available, and it is
unclear whether chronic consumption of functional foods
with added plant stanol or sterol esters would prevent
development of atheromatous coronary disease. A review
of the published papers [44] suggests that prevention of
coronary events would be approximately 25% with a
0.6 mmol/l (approximately 10%) reduction in serum cho-
lesterol with esterified phytosterols.
A recent long-term simvastatin prevention trial (4S) [15]
showed that coronary patients with high baseline choles-
terol absorption (defined by high serum cholestanol and
plant sterol :cholesterol ratios) did not experience a reduc-
tion in incidence of coronary events, whereas those with low
absorption were responders [45]. In addition, those with
high absorption, in contrast to those with low absorption,
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exhibited gradually increased plant sterol levels over a 5-
year period and tended to have a lesser cholesterol reduc-
tion; these two factors are presumed to contribute to
nonresponsiveness to event reduction [46]. It was assumed
that additional use of plant stanol esters would be benefi-
cial. In fact, combination of inhibitors of cholesterol synthe-
sis (statins) and absorption (stanol esters) had a clear
additive effect on both cholesterol and plant sterol reduc-
tions, with statins also eliminating the compensatory
increase in cholesterol synthesis caused by stanol esters
[47,48]. A combination of stanol ester margarine consump-
tion with long-term statin treatment in individuals with high
baseline cholesterol absorption lowered serum cholesterol
more consistently than in those with low baseline absorp-
tion, and plant sterol reductions were more consistent [49].
In a small, controlled, randomized study (Gylling H, Mietti-
nen TA, unpublished data), treatment of patients with acute
myocardial infarction immediately after hospital discharge
with stanol ester margarine plus lovastatin lowered serum
LDL-cholesterol by almost 50% when compared with a
control group that consumed margarine only. In contrast to
other preliminary observations in acute coronary syndromes
[50,51], clinical coronary events were similar in the two
groups during the first posthospital year. This is not unusual,
because differences in coronary events are not evident for
more than 1 year after cholesterol reduction [15].
Conclusion
By dietary means, it is possible to diminish total and coro-
nary mortality, coronary morbidity, and other atherosclerotic
manifestations. The beneficial effects are obtained by lower-
ing serum cholesterol level and stabilizing the plaque, but
also by improving the endothelial function, decreasing the
risk of arrhythmias and reducing blood-clotting tendency.
These results can be obtained by modest and feasible
dietary changes, which can be supported by adding plant
stanol and sterol esters to the diet. Accordingly, in order to
reduce coronary artery disease and to interfere with the ath-
erosclerotic process, a population-based dietary coun-
selling seems to be justifiable.
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